<DOC>
	<DOCNO>NCT01499888</DOCNO>
	<brief_summary>The investigator propose determine engraftment transplant relate morbidity mortality non-myeloablative allogeneic hematopoietic stem cell transplant protocol use immune- suppressive agent low-dose total body irradiation ( TBI ) without standard chemotherapy patient aggressive sickle cell disease candidate experience complication hydroxyurea therapy . Fully HLA match sibling use donor hematopoietic stem cell reduce risk morbidity mortality cohort patient .</brief_summary>
	<brief_title>Ph I/II Study Allogeneic SCT Clinically Aggressive Sickle Cell Disease ( SCD )</brief_title>
	<detailed_description>Sickle cell disease inherit defect cause mutation Beta globin gene affect red blood cell . Symptoms begin 6 month life often lead debilitate vaso-occlusive pain crisis , acute insult vital organ system , chronic organ injury , decrease survival median survival estimate 42 year men 48 year woman . Several cohort study identify clinical laboratory predictor decrease survival include acute complication , chronic complication sickle cell disease . Hydroxyurea FDA approve drug help ameliorate symptom associate sickle cell disease . Two nonrandomized study suggest reduction mortality 17 year long term hydroxyurea treatment . However , mortality rate still high hydroxyurea cohort 43.1 % 38.1 % patient rise fetal hemoglobin indicate significant percentage patient still aggressive disease despite hydroxyurea treatment . Hydroxyurea therapy also seem prevent development pulmonary hypertension . In pediatric population , patient clinically improve despite optimized hydroxyurea management offer allogeneic stem cell transplantation . Until recently , option limit adult sickle cell disease aggressive disease despite hydroxyurea therapy . Most rely chronic red blood cell transfusion carry significant risk infection , iron overload , alloimmunization . Up 50 % patient sickle cell disease chronic transfusion therapy develop allo-antibodies make transfusion difficult high potential hemolytic transfusion reaction . Patients sickle cell disease often chronic underlie organ disease effect chemotherapy may unpredictable potentially harmful , make low dose TBI attractive safer modality conditioning . The investigator propose determine engraftment transplant relate morbidity mortality non-myeloablative allogeneic hematopoietic stem cell transplant protocol use immune- suppressive agent low-dose total body irradiation ( TBI ) without standard chemotherapy patient aggressive sickle cell disease candidate experience complication hydroxyurea therapy . Fully HLA match sibling use donor hematopoietic stem cell reduce risk morbidity mortality cohort patient . An optional correlative trial conduct compare ocular finding stem cell transplantation finding stem cell transplantation . Anterior posterior ocular examination well objective test perform subject .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients sickle cell disease , subtype Hgb SS , SC , SB disease chronic transfusion therapy prior stroke patient intolerant hydroxyurea therapy treat hydroxyurea therapy complicate least one following : Stroke central nervous system event last long 24 hour Frequent vasoocclusive pain episode , define ≥ 3 per year require emergency room visit hospital admission Recurrent episodes priapism , define ≥ 2 per year require emergency room visit Acute chest syndrome recurrent hospitalization , define ≥ 2 lifetime event Redcell alloimmunization ( ≥ 2 antibody ) longterm transfusion therapy Bilateral proliferative retinopathy major visual impairment least one eye Osteonecrosis 2 joint Sickle cell nephropathy Stage I II sickle lung disease Symptoms pulmonary hypertension mean pulmonary artery pressure &gt; 25mmHg Age 1860 year Karnofsky performance status 70 high ( Appendix A ) Adequate cardiac function , define leave ventricular ejection fraction ≥ 40 % Adequate pulmonary function , define diffusion lung capacity carbon monoxide ≥ 50 % Estimated GFR ≥ 50mL/min calculate modify MDRD equation ALT ≤ 3x upper limit normal Patient able willing sign inform consent Patient HLAidentical match related donor Evidence chronic active hepatitis cirrhosis HIVpositive Current pregnancy History noncompliance medication medical care</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Subtype Hgb SS</keyword>
	<keyword>Subtype Hgb SC</keyword>
	<keyword>Subtype Hgb SB</keyword>
	<keyword>Chronic Transfusion Therapy</keyword>
	<keyword>Prior Stroke</keyword>
	<keyword>Allogeneic</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Total Body Irradiation</keyword>
	<keyword>Hydroxyurea Intolerant</keyword>
</DOC>